Search results
Results from the WOW.Com Content Network
In July 2021, the U.S. Food and Drug Administration (FDA) approved Tanovea to treat lymphoma in dogs. [6] Lymphoma, also called lymphosarcoma, is a type of cancer that can affect many species, including dogs. [6] Rabacfosadine is the first conditionally approved new animal drug for dogs to achieve the FDA's full approval. [6]
Molidustat is a drug which acts as an HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells. It is in Phase III clinical trials for the treatment of anemia caused by chronic kidney disease .
In 2004, 3M obtained FDA approval to market imiquimod as a treatment for superficial basal cell carcinoma. [ 21 ] In 2006, 3M sold its pharmaceutical business in the Americas to Graceway Pharmaceuticals , its European pharmaceutical business to Meda AB , and its pharmaceutical business in other territories to two private equity firms.
How a new FDA-approved drug can — and can’t — help people with Alzheimer’s November 21, 2024 at 12:28 PM If you have a loved one with Alzheimer’s disease, you may have read about a newly ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Avelumab is FDA approved for the treatment of metastatic merkel-cell carcinoma. It failed phase III clinical trials for gastric cancer. [33] Durvalumab (Imfinzi) is a fully human IgG1 antibody developed by AstraZeneca. Durvalumab is FDA approved for the treatment of urothelial carcinoma and unresectable non-small cell lung cancer after ...
In 2015, the FDA granted lorlatinib orphan drug status for the treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer. [ 13 ] Lorlatinib was approved for medical use in the United States in November 2018, [ 8 ] and in the European Union in May 2019.
The drug was approved in January under the FDA’s Accelerated Approval pathway, which allows the organization to approve drugs for serious conditions where there is an unmet medical need, based ...